Mirus Bio Corporation

Mirus Corporation

Roche Madison Inc.

Other

The General Hospital Corporation

Arrowhead Pharmaceuticals, Inc.

Quintessence Biosciences, Inc.

Mirns Bio Corporation

Vladimir S Trubetskoy

Jon Asher Wolff

James E Hagstrom

Vladimir G Budker

Sean D Monahan

David B Rozema

Paul Michael Slattum

Lisa J Hanson

Vladimir P Torchilin

Darren H Wakefield

So Wong

Gerald L Wolf

Jason Klein

David L Lewis

Steven B Kanner

Tao Pei

Zhen Li

Lauren Almeida

Aaron Almeida

Stacey Melquist

Aaron G Loomis

G Scott Gazelle

John A Kink

Hans Herweijer

Laura Strong

Marcos Intaglietta

Lori Higgs

Paul Slattum

Mark N Shahan

Amy Tsai

Lauren J Almeida

RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.

Compositions and methods for inhibiting gene expression of LPA

The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).

Modified ribonucleases

Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.

Compositions and processes using siRNA, amphipathic compounds and polycations

An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.

Polyampholytes for delivering polyions to a cell

Cyclic amidinium containing compounds and their methods of preparation are described. Compositions containing these compounds facilitate delivery of biologically active polymers to cells in vitro and in vivo.

Compositions for delivering nucleic acids to cells

A method of forming polymers in the presence of nucleic acid using template polymerization. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.

Process of making a compound by forming a polymer from a template drug

Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.

Formation of polyampholytes in the presence of a polyion

An ionic polymer is utilized in 'recharging' (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired net charge.

Charge reversal of polyion complexes

Compositions and methods for drug delivery using pH sensitive molecules

A method of forming polymers in the presence of nucleic acid using template polymerization. Also, a method of having the polymerization occur in heterophase systems. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte complex.

We describe a process for generating multilayer particles comprising condensing a polymer with an oppositely charged polymer to form a particle and sequentially adding oppositely charged polymers to the particle forming at least three layers of polymers. The process is used to form a composition for delivering a biologically active compound to a cell.

Process for generating multilayered particles

Growing community of inventors

Middleton, WI, United States of America

Vladimir S Trubetskoy